Table 2.

Urinary parameters over the course of treatment

	Empagliflozin (n = 40)	Placebo (n = 39)	P‐value
Spot urinary sodium (mmol/L)
Baseline	90 ± 31	87 ± 35	0.706
24 h	69 ± 28	85 ± 37	0.040
48 h	56 ± 29	79 ± 44	0.011
72 h	63 ± 41	70 ± 27	0.400
96 h	56 ± 29	69 ± 32	0.089
30 days	60 ± 30	56 ± 28	0.683
Fractional excretion of sodium (%)
Baseline	2.1 (0.9–4.1)	2.2 (0.9–4.4)	0.964
24 h	1.4 (0.9–2.4)	1.5 (0.6–3.2)	0.874
48 h	1.0 (0.3–1.7)	1.4 (0.7–2.1)	0.256
72 h	1.4 (0.8–1.7)	1.0 (0.6–2.3)	0.840
96 h	0.8 (0.4–1.9)	1.0 (0.7–1.7)	0.476
30 days	0.7 (0.3–1.7)	0.7 (0.4–2.0)	0.388
Spot urinary glucose (mmol/L)
Baseline	0.2 (0.1–0.3)	0.1 (0.1–0.2)	0.264
24 h	50.4 (17.1–94.8)	0.2 (0.1–0.3)	<0.001
48 h	41.3 (17.2–79.1)	0.2 (0.1–0.3)	<0.001
72 h	35.2 (16.2–96.2)	0.2 (0.1–0.3)	<0.001
96 h	30.3 (9.9–75.2)	0.2 (0.1–0.4)	<0.001
30 days	13.1 (1.6–58.9)	0.2 (0.1–0.3)	<0.001
Fractional excretion of glucose (%)
Baseline	0.1 (0.1–0.1)	0.1 (0.0–0.1)	0.890
24 h	21.8 (10.1–29.8)	0.1 (0.1–0.1)	<0.001
48 h	13.6 (5.4–24.0)	0.1 (0.0–0.1)	<0.001
72 h	16.0 (4.2–24.4)	0.1 (0.0–0.1)	<0.001
96 h	6.0 (2.5–21.8)	0.1 (0.0–0.1)	<0.001
Spot urinary urea (mmol/L)
Baseline	108.0 (60.8–142.1)	97.5 (77.6–139.5)	0.881
24 h	136.0 (93.3–172.7)	124.0 (91.3–191.6)	0.935
48 h	160.2 (116.0–194.0)	159.3 (111.3–105.7)	0.840
72 h	154.5 (122.9–185.0)	157.5 (128.5–207.5)	0.426
96 h	179.6 (121.0–256.7)	172.2 (144.9–233.0)	0.427
30 days	214.0 (141.0–272.6)	166.6 (85.2–294.5)	0.333
Fractional excretion of urea (%)
Baseline	37.9 (30.3–45.0)	37.6 (28.0–48.5)	0.984
24 h	33.1 (28.6–41.9)	35.3 (21.4–43.0)	0.664
48 h	29.6 (22.2–39.3)	30.5 (25.7–39.7)	0.572
72 h	31.1 (26.3–37.1)	32.0 (24.9–39.2)	0.952
96 h	32.4 (24.2–38.0)	33.5 (29.5–39.0)	0.346